RECONSTITUTION GUIDANCE
RECONSTITUTION FOR FDA-APPROVED GLABELLAR LINES DOSE

FOR EVERY 100-UNIT DAXXIFY® VIAL, RECONSTITUTE WITH 1.2 ML OF STERILE SALINE*

Inject 0.1 mL into 5 glabellar lines injection points
40U (0.18 ng) in 0.5 mL per glabellar lines treatment
0.1 mL contains 8 units once reconstituted

PREPARATION

1. USE 1.2 ML OF DILUENT
   To reconstitute DAXXIFY®, draw up 1.2 mL of sterile saline.\(^*\)

2. INJECT DILUENT SLOWLY
   Clean the exposed rubber stopper on the DAXXIFY® vial with an alcohol swab. Slowly inject the saline diluent into the DAXXIFY® vial.\(^1\)

3. MIX THE SOLUTION
   Swirl gently to ensure mixing. Record the date of the reconstitution on vial/syringe sticker.\(^1\)

4. INSPECT THE SOLUTION
   The reconstituted solution should be clear to slightly opalescent, colorless, and free of particulate matter. The reconstituted solution may temporarily appear cloudy. **DO NOT USE** if the solution remains cloudy or discolored or contains flakes or particles.\(^1\)

5. READY FOR TREATMENT
   Draw an appropriate dose into a new sterile syringe.

*Preservative-free

Watch the step-by-step DAXXIFY® reconstitution video
More than 70% of injectors do not reconstitute a conventional neuromodulator following prescribing information guidance. Using a different reconstitution volume can lead to unintended safety consequences. To mitigate this safety risk, use the table below to ensure the FDA-approved 40U dose of DAXXIFY® (daxibotulinumtoxinA-lanm) injection is administered.²

### CONVENTIONAL NEUROMODULATOR

(100-unit vial, 0.18 ng per 20U treatment)

<table>
<thead>
<tr>
<th>RECONSTITUTION VOLUME</th>
<th>1.0 mL</th>
<th>2.0 mL</th>
<th>2.5 mL</th>
<th>3.0 mL</th>
<th>4.0 mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>GLABELLAR LINES</td>
<td>20U</td>
<td>20U</td>
<td>20U</td>
<td>20U</td>
<td>20U</td>
</tr>
<tr>
<td>TREATMENT DOSE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TOTAL GLABELLAR LINES</td>
<td>0.2 mL</td>
<td>0.4 mL</td>
<td>0.5 mL</td>
<td>0.6 mL</td>
<td>0.8 mL</td>
</tr>
<tr>
<td>TREATMENT VOLUME</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PUSH VOLUME</td>
<td>0.04 mL</td>
<td>0.08 mL</td>
<td>0.10 mL</td>
<td>0.12 mL</td>
<td>0.16 mL</td>
</tr>
<tr>
<td>For each of the 5 injection points (and the corresponding units)</td>
<td>(4 Units)</td>
<td>(4 Units)</td>
<td>(4 Units)</td>
<td>(4 Units)</td>
<td>(4 Units)</td>
</tr>
</tbody>
</table>

### DAXXIFY®

(100-unit vial, 0.18 ng per 40U treatment)

<table>
<thead>
<tr>
<th>RECONSTITUTION VOLUME</th>
<th>0.5 mL</th>
<th>1.0 mL</th>
<th>1.2 mL</th>
<th>1.5 mL</th>
<th>2.0 mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>ON LABEL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GLABELLAR LINES</td>
<td>40U</td>
<td>40U</td>
<td>40U</td>
<td>40U</td>
<td>40U</td>
</tr>
<tr>
<td>TREATMENT DOSE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TOTAL GLABELLAR LINES</td>
<td>0.2 mL</td>
<td>0.4 mL</td>
<td>0.5 mL</td>
<td>0.6 mL</td>
<td>0.8 mL</td>
</tr>
<tr>
<td>TREATMENT VOLUME</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PUSH VOLUME</td>
<td>0.04 mL</td>
<td>0.08 mL</td>
<td>0.10 mL</td>
<td>0.12 mL</td>
<td>0.16 mL</td>
</tr>
<tr>
<td>For each of the 5 injection points (and the corresponding units)</td>
<td>(8 Units)</td>
<td>(8 Units)</td>
<td>(8 Units)</td>
<td>(8 Units)</td>
<td>(8 Units)</td>
</tr>
</tbody>
</table>

**INDICATION**

DAXXIFY® (daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.

Please see Important Safety Information, including Boxed Warning, on back.
- **DRAW UP 0.5 ML IN 2 SYRINGES**
  0.3 mL in one syringe and 0.2 mL in another syringe

- **EACH TICK MARK REPRESENTS 0.01 ML AND WOULD CONTAIN 0.8U**

*Representation is of common 1.0 mL syringe but some syringes may label barrels differently (ie, 0.01 mL tick marks represent 1U). Please check your syringe tick marks carefully.*
40U (0.18 ng)  
DAXXIFY®  
Reconstituted with 1.2 mL sterile saline† for glabellar lines treatment

20U (0.18 ng)  
BOTOX® COSMETIC  
Reconstituted with 2.5 mL sterile saline† for glabellar lines treatment

20U (0.18 ng)  
BOTOX® COSMETIC  
Reconstituted with 2.5 mL sterile saline† for glabellar lines treatment

20U (0.18 ng)  
BOTOX® COSMETIC  
Reconstituted with 2.5 mL sterile saline† for glabellar lines treatment

40U (0.18 ng)  
DAXXIFY®  
Reconstituted with 1.2 mL sterile saline† for glabellar lines treatment

†Preservative-free
• **DRAW UP 0.4 ML IN 2 SYRINGES**
  0.24 mL in one syringe and
  0.16 mL in another syringe

  ![0.3 mL Syringe Diagram](image)

  • **EACH TICK MARK REPRESENTS 0.01 ML AND WOULD CONTAIN 1U**

  ![0.5 mL Syringe Diagram](image)

• **DRAW UP 0.4 ML IN A SYRINGE**

  ![1.0 mL Syringe Diagram](image)

  • **EACH TICK MARK REPRESENTS 0.02 ML AND WOULD CONTAIN 2U**

*Representation is of common 1.0 mL syringe but some syringes may label barrels differently (ie, 0.01 mL tick marks represent 1U). Please check your syringe tick marks carefully.*
20U (0.18 ng)  
BOTOX® COSMETIC  
Reconstituted with 2.0 mL sterile saline† for glabellar lines treatment

40U (0.18 ng)  
DAXXIFY®  
Reconstituted with 1.0 mL sterile saline† for glabellar lines treatment

†Preservative-free
IMPORTANT SAFETY INFORMATION

Contraindications
DAXXIFY® contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).

Warnings and Precautions
Please refer to Boxed Warning for Distant Spread of Toxin Effect.

The potency Units of DAXXIFY® are not interchangeable with other preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.

Adverse Reactions
The most commonly observed adverse reactions (≥1%) were headache (6%), eyelid ptosis (2%) and facial paresis (1%).

Drug Interactions
Co-administration of DAXXIFY® and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY® may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY® is unknown.

Use in Specific Populations
DAXXIFY® is not recommended for use in children or pregnant women.

Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide.

REFERENCES
1. DAXXIFY® Prescribing Information. Revance Therapeutics, Inc; 2022.